Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$40.88 USD
+0.67 (1.67%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $40.92 +0.04 (0.10%) 4:18 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 8/1/24 |
---|---|
Current Quarter | -1.65 |
EPS Last Quarter | -2.03 |
Last EPS Surprise | -18.02% |
ABR | 1.14 |
Earnings ESP
|
-1.07% |
---|---|
Current Year | -6.46 |
Next Year | -5.22 |
EPS (TTM) | -8.03 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 123.42M | 132.62M | 511.13M | 599.31M |
# of Estimates | 9 | 9 | 9 | 9 |
High Estimate | 130.00M | 137.60M | 519.07M | 653.56M |
Low Estimate | 120.00M | 121.90M | 501.50M | 544.20M |
Year ago Sales | 108.31M | 98.05M | 434.25M | 511.13M |
Year over Year Growth Est. | 13.95% | 35.25% | 17.70% | 17.25% |
Earnings Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -1.65 | -1.50 | -6.46 | -5.22 |
# of Estimates | 11 | 9 | 12 | 11 |
Most Recent Consensus | -1.70 | -1.58 | -6.29 | -3.88 |
High Estimate | -1.41 | -1.21 | -5.84 | -3.88 |
Low Estimate | -1.93 | -1.84 | -7.44 | -6.61 |
Year ago EPS | -2.25 | -2.23 | -8.25 | -6.46 |
Year over Year Growth Est. | 26.67% | 32.74% | 21.70% | 19.06% |
Agreement - Estimate Revisions
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 1 |
Up Last 30 Days | 3 | 3 | 4 | 4 |
Up Last 60 Days | 2 | 3 | 3 | 2 |
Down Last 7 Days | 1 | 0 | 1 | 0 |
Down Last 30 Days | 3 | 1 | 3 | 3 |
Down Last 60 Days | 3 | 1 | 4 | 5 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -1.65 | -1.50 | -6.46 | -5.22 |
7 Days Ago | -1.64 | -1.50 | -6.43 | -5.22 |
30 Days Ago | -1.63 | -1.51 | -6.49 | -5.05 |
60 Days Ago | -1.64 | -1.51 | -6.47 | -4.92 |
90 Days Ago | -1.56 | -1.50 | -6.34 | -5.10 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -1.67 | -1.49 | -6.47 | -5.20 |
Zacks Consensus Estimate | -1.65 | -1.50 | -6.46 | -5.22 |
Earnings ESP | -1.07% | 0.89% | -0.23% | 0.48% |
Surprise - Reported Earnings History
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -2.03 | -1.52 | -2.23 | -2.25 | NA |
Estimate | -1.72 | -1.65 | -2.08 | -2.11 | NA |
Difference | -0.31 | 0.13 | -0.15 | -0.14 | -0.12 |
Surprise | -18.02% | 7.88% | -7.21% | -6.64% | -6.00% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more